Bluejay Diagnostics, Inc. (BJDX) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-07

Key Insights

Bluejay Diagnostics disclosed Q1 2026 financial results and corporate update via press release on May 7, 2026, indicating the company is actively communicating with investors about operational performance.
As an emerging growth company, BJDX has flexibility in financial reporting requirements, which may affect the depth and timing of financial disclosures compared to larger public companies.
The filing is a routine 8-K containing only a corporate update and quarterly results without any material agreements, executive changes, or significant corporate events that would typically drive stock movement.

Want the newest filings?

This analysis covers the filing from 2026-05-07. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-04-07

Bluejay Diagnostics, Inc. (BJDX) provided an update on the patient enrollment status for its ongoing SYMON-II clinical trial, which is a key development for the company.
As an emerging growth company, BJDX has the option to take advantage of the extended transition period for compliance with new or revised financial accounting standards, which could impact investor confidence.
The company's shares trade on the Nasdaq Stock Market, indicating it has met the exchange's listing requirements and provides investors with access to the public markets.

Filed: 2026-03-17

Bluejay Diagnostics has secured $125,000 in funding through a private placement of common stock, with participation from the CEO, board chair, and other directors.
The company has chosen to issue the shares in a private placement rather than a public offering, suggesting they may be preserving capital or avoiding dilution.
The fact that insiders are investing their own capital in the company is a positive signal about their confidence in Bluejay's prospects.

Filed: 2026-03-16

Bluejay Diagnostics, Inc. (BJDX) has responded to a letter received from NorthStrive Fund II LP, indicating potential shareholder engagement.
The filing does not contain any information about the company's financial performance, operations, or other material updates, suggesting this is a routine regulatory filing.
As an emerging growth company, Bluejay Diagnostics may have greater flexibility in financial reporting and accounting standards, which could impact transparency for investors.

Filed: 2026-03-12

Bluejay Diagnostics announced that an abstract related to their product candidate, the Symphony™ IL-6 Test, has been accepted for presentation at the 2026 Society of Academic Emergency Medicine Annual Meeting. This suggests potential progress in the development and validation of their diagnostic test.
The company is an emerging growth company, which provides insights into their stage of development and potential growth opportunities.
Bluejay Diagnostics is headquartered in Acton, MA, which provides context on the company's location and potential access to relevant research and development resources.

Filed: 2026-03-06

Bluejay Diagnostics provided a corporate and strategic update, as well as financial results for the year ended December 31, 2025. This suggests the company is making progress and has information to share with investors.
The company is classified as an emerging growth company, which means it may have less stringent reporting requirements and could provide more flexibility in its financial disclosures.
Bluejay Diagnostics' shares trade on the Nasdaq stock exchange, indicating it has met the listing requirements and is publicly traded.

Filed: 2026-02-20

Bluejay Diagnostics issued a press release providing an update on certain warrant and capitalization matters, indicating potential changes to the company's capital structure.
The filing does not provide details on the specific warrant and capitalization updates, so the impact on shareholders is unclear from the information provided.
As an emerging growth company, Bluejay Diagnostics may be taking advantage of certain regulatory exemptions, which could impact financial reporting and disclosure requirements.

Filed: 2026-02-18

Bluejay Diagnostics, Inc. (BJDX) provided an update on its clinical study enrollment and manufacturing readiness initiatives, indicating progress in key operational areas.
The company's update was furnished in an 8-K filing, suggesting the information may be material to investors.
As an emerging growth company, Bluejay Diagnostics may have the option to take advantage of extended transition periods for complying with new or revised financial accounting standards.

Filed: 2026-01-30

Bluejay Diagnostics, Inc. (BJDX) has implemented a 1-for-4 reverse stock split, reducing the number of outstanding shares from 2,834,133 to approximately 708,533.
The reverse split did not alter the par value or voting rights of the common stock and was approved by shareholders at the 2025 Annual Meeting.
The company's trading symbol 'BJDX' remains unchanged, and the stock began trading on a post-split basis on the Nasdaq Capital Market on January 29, 2026.

Filed: 2025-12-30

Bluejay Diagnostics, Inc. provided an update on the status of its commercial-scale IL-6 antibody production, which is a critical step towards commercialization of its key diagnostic product.
The company is an emerging growth company, which suggests it may have higher growth potential but also higher risk compared to more established firms.
No financial or operational details were provided in this 8-K filing, indicating it is likely a routine regulatory update rather than a major business development.

Other reports for Bluejay Diagnostics, Inc.

Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.